Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy

Journal of the American Society of Nephrology

Volumn 26, Issue 8, 2015, Pages 1889-1904

  Oltean, Sebastian ^a   Qiu, Yan ^a   Ferguson, Joanne K ^a   Stevens, Megan ^a   Neal, Chris ^a   Russell, Amy ^a   Kaura, Amit ^a   Arkill, Kenton P ^a   Harris, Kirstie ^a   Symonds, Clare ^a   Lacey, Katja ^a   Wijeyaratne, Lihini ^a   Gammons, Melissa ^a   Wylie, Emma ^a,b   Hulse, Richard P ^c   Alsop, Chloe ^a   Cope, George ^b   Damodaran, Gopinath ^a   Betteridge, Kai B ^a   Ramnath, Raina ^b   Satchell, Simon C ^b   Foster, Rebecca R ^b   Ballmer Hofer, Kurt ^d   Donaldson, Lucy F ^a,c   Barratt, Jonathan ^e   Baelde, Hans J ^f   Harper, Steven J ^a   Bates, David O ^g   Salmon, Andrew H J ^a,b   more..

^a School of Physiology and Pharmacology   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c School of Life Sciences   (United States)

^d PAUL SCHERRER INSTITUTE   (Switzerland)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; GLUCOSE; MESSENGER RNA; PROTECTIVE AGENT; RENAL PROTECTIVE AGENT; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR A 165A; VASCULAR ENDOTHELIAL GROWTH FACTOR A 165B; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ADULT; ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG MEGADOSE; ENDOTHELIUM CELL; GENE OVEREXPRESSION; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION; GLUCOSE BLOOD LEVEL; GLYCOCALYX; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; IN VIVO STUDY; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; KIDNEY INJURY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN URINE LEVEL; PROTEINURIA; RENAL PROTECTION; SIGNAL TRANSDUCTION; THICKNESS; TISSUE REPAIR; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION; WATER PERMEABILITY; ANIMAL; C57BL MOUSE; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; METABOLISM; PODOCYTE; PRECLINICAL STUDY; TRANSGENIC MOUSE; UMBILICAL VEIN ENDOTHELIAL CELL;

ALBUMINURIA; ANIMALS; DIABETIC NEPHROPATHIES; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; GLOMERULAR FILTRATION RATE; GLYCOCALYX; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; PODOCYTES; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84938946202     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014040350     Document Type: Article

References (56)

1. Gilbertson DT, Liu J, Xue JL, Louis TA, Solid CA, Ebben JP, Collins AJ: Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 16: 3736-3741, 2005
2. Frank RN: Diabetic retinopathy. N Engl J Med 350: 48-58, 2004
3. Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ: Prevalence andcharacteristics of painfuldiabetic neuropathy ina largecommunity-based diabetic populationin the U.K. Diabetes Care 34: 2220-2224, 2011
4. Forbes JM, Cooper ME: Mechanisms of diabetic complications. Physiol Rev 93: 137-188, 2013
5. Rask-Madsen C, King GL: Kidney complications: Factors that protect the diabetic vasculature. Nat Med 16: 40-41, 2010
6. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, Corat MA, Zeier M, Blessing E, Oh J, Gerlitz B, Berg DT, Grinnell BW, Chavakis T, Esmon CT, Weiler H, Bierhaus A, Nawroth PP: Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 13: 1349-1358, 2007
7. Sivaskandarajah GA, Jeansson M, Maezawa Y, Eremina V, Baelde HJ, Quaggin SE: Vegfa protects the glomerular microvasculature in diabetes. Diabetes 61: 2958-2966, 2012
8. Foster RR, Hole R, Anderson K, Satchell SC, Coward RJ, Mathieson PW, Gillatt DA, Saleem MA, Bates DO, Harper SJ: Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol 284: F1263-F1273, 2003
9. Sison K, Eremina V, Baelde H, Min W, Hirashima M, Fantus IG, Quaggin SE: Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 21: 1691-1701, 2010
10. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 1129-1136, 2008
11. Baelde HJ, Eikmans M, Lappin DW, Doran PP, Hohenadel D, Brinkkoetter PT, van derWoude FJ, Waldherr R, Rabelink TJ, de Heer E, Bruijn JA: Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int 71: 637-645, 2007
12. Saito D, Maeshima Y, Nasu T, Yamasaki H, Tanabe K, Sugiyama H, Sonoda H, Sato Y, Makino H: Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis. Am J Physiol Renal Physiol 300: F873-F886, 2011
13. Bates DO: Vascular endothelial growth factors and vascular permeability. Cardiovasc Res 87: 262-271, 2010
14. Mathieson PW: How much VEGF do you need? J Am Soc Nephrol 17: 602-603, 2006
15. Qiu Y, Ferguson J, Oltean S, Neal CR, Kaura A, Bevan H, Wood E, Sage LM, Lanati S, Nowak DG, Salmon AH, Bates D, Harper SJ: Over-expression of VEGF165b in podocytes reduces glomerular permeability. J Am Soc Nephrol 21: 1498-1509, 2010
16. Hua J, Spee C, Kase S, Rennel ES, Magnussen AL, Qiu Y, Varey A, Dhayade S, Churchill AJ, Harper SJ, Bates DO, Hinton DR: Recombinant human VEGF165b inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 51: 4282-4288, 2010
17. Manetti M, Guiducci S, Romano E, Ceccarelli C, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, Matucci-Cerinic M: Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res 109: e14-e26, 2011
18. Schumacher VA, Jeruschke S, Eitner F, Becker JU, Pitschke G, Ince Y, Miner JH, Leuschner I, Engers R, Everding AS, Bulla M, Royer-Pokora B: Impaired glomerular maturation and lack of VEGF165bin Denys-Drash syndrome. J Am Soc Nephrol 18: 719-729, 2007
19. Veron D, Bertuccio CA, Marlier A, Reidy K, Garcia AM, Jimenez J, Velazquez H, Kashgarian M, Moeckel GW, Tufro A: Podocyte vascular endothelial growth factor (Vegfiw) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia 54: 1227-1241, 2011
20. Oltean S, Neal CR, Mavrou A, Patel P, Ahad T, Alsop C, Lee T, Sison K, Qiu Y, Harper SJ, Bates DO, Salmon AH: VEGF165b overexpression restores normal glomerular water permeability in VEGF164-overexpressing adult mice. Am J Physiol Renal Physiol 303: F1026-F1036, 2012
21. Rennel ES, Hamdollah-Zadeh MA, Wheatley ER, Magnussen A, Schüler Y, Kelly SP, Finucane C, Ellison D, Cebe-Suarez S, Ballmer-Hofer K, Mather S, Stewart L, Bates DO, Harper SJ: Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. Eur J Cancer 44: 1883-1894, 2008
22. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ: VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 62: 4123-4131, 2002
23. Harper SJ, Bates DO: VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 8: 880-887, 2008
24. Magnussen AL, Rennel ES, Hua J, Bevan HS, Beazley Long N, Lehrling C, Gammons M, Floege J, Harper SJ, Agostini HT, Bates DO, Churchill AJ: VEGF-A165b is cytoprotective and antiangiogenic in the retina. Invest Ophthalmol Vis Sci 51: 4273-4281, 2010
25. Rennel E, Waine E, Guan H, Schüler Y, Leenders W, Woolard J, Sugiono M, Gillatt D, Kleinerman E, Bates D, Harper S: The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer 98: 1250-1257, 2008
26. Oltean S, Gammons M, Hulse R, Hamdollah-Zadeh M, Mavrou A, Donaldson L, Salmon AH, Harper SJ, Ladomery MR, Bates DO: SRPK1 inhibition in vivo: Modulation of VEGF splicing and potential treatment for multiple diseases. Biochem Soc Trans 40: 831-835, 2012
27. Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M, Schumacher VA, Harper SJ, Hinton DR, Bates DO, Ladomery MR: WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell 20: 768-780, 2011
28. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ, Woolard J, Ladomery MR, Bates DO: Regulationof vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: A novel therapeutic strategy for angiogenesis. J Biol Chem 285: 5532-5540, 2010
29. Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO: Expression of pro-and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 121: 3487-3495, 2008
30. Cébe Suarez S, Pieren M, Cariolato L, Arn S, Hoffmann U, Bogucki A, Manlius C, Wood J, Ballmer-Hofer K: A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci 63: 2067-2077, 2006
31. Kawamura H, Li X, Harper SJ, Bates DO, Claesson-Welsh L: Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res 68: 4683-4692, 2008
32. Kim HW, Lim JH, Kim MY, Chung S, Shin SJ, Chung HW, Choi BS, Kim YS, Chang YS, Park CW: Long-term blockade of vascular endothelial growth factor receptor-2 aggravates the diabetic renal dysfunction associated with inactivation of the Akt/eNOS-NO axis. Nephrol Dial Transplant 26: 1173-1188, 2011
33. Bates DO, Mavrou A, Qiu Y, Carter JG, Hamdollah-Zadeh M, Barratt S, Gammons MV, Millar AB, Salmon AH, Oltean S, Harper SJ: Detection of VEGF-A(xxx)b isoforms in human tissues. PLoS ONE 8: e68399, 2013
34. Harris S, Craze M, Newton J, Fisher M, Shima DT, Tozer GM, Kanthou C: Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist?Acautionary tale. PLoS ONE 7: e35231, 2012
35. Kikuchi R, Nakamura K, MacLauchlan S, Ngo DT, Shimizu I, Fuster JJ, Katanasaka Y, Yoshida S, Qiu Y, Yamaguchi TP, Matsushita T, Murohara T, Gokce N, Bates DO, Hamburg NM, Walsh K: An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease [published online ahead of print November 2, 2014]. Nat Med doi: 10.1038/nm.3703
36. Rippe C, Rippe A, Torffvit O, Rippe B: Size and charge selectivity of the glomerular filter in early experimental diabetes in rats. Am J Physiol Renal Physiol 293: F1533-F1538, 2007
37. Russo LM, Sandoval RM, Campos SB, Molitoris BA, Comper WD, Brown D: Impaired tubular uptake explains albuminuria in early diabetic ne-phropathy. J Am Soc Nephrol 20: 489-494, 2009
38. Thomson SC, Vallon V, Blantz RC: Kidney function in early diabetes: The tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol 286: F8-F15, 2004
39. Breyer MD: Translating experimental diabetic nephropathy studies from mice to men. Contrib Nephrol 170: 156-164, 2011
40. Tesch GH, Lim AK: Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. Am J Physiol Renal Physiol 300: F301-F310, 2011
41. Weil EJ, Lemley KV, Mason CC, Yee B, Jones LI, Blouch K, Lovato T, Richardson M, Myers BD, Nelson RG: Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int 82: 1010-1017, 2012
42. Salmon AH, Satchell SC: Endothelial glycocalyx dysfunction in disease: Albuminuria and increased microvascular permeability. J Pathol 226: 562-574, 2012
43. Salmon A, Ferguson J, Burford J, Gevorgyan A, Nakano D, Harper S, Bates D, Peti-Peterdi J: Widespread loss of endothelial glycocalyx links albuminuria and systemic vascular dysfunction. J Am Soc Nephrol 23: 1339-1350, 2012
44. Broekhuizen LN, Lemkes BA, Mooij HL, Meuwese MC, Verberne H, Holleman F, Schlingemann RO, Nieuwdorp M, Stroes ES, Vink H: Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 53: 2646-2655, 2010
45. Nieuwdorp M, Mooij HL, Kroon J, Atasever B, Spaan JA, Ince C, Holleman F, Diamant M, Heine RJ, Hoekstra JB, Kastelein JJ, Stroes ES, Vink H: Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 55: 1127-1132, 2006
46. Salmon AH, Neal CR, Bates DO, Harper SJ: Vascular endothelial growth factor increases the ultrafiltration coefficient in isolated intact Wistar rat glomeruli. J Physiol 570: 141-156, 2006
47. Satchell SC, Anderson KL, Mathieson PW: Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol 15: 566-574, 2004
48. Salmon AH, Neal CR, Sage LM, Glass CA, Harper SJ, Bates DO: Angiopoietin-1 altersmicrovascular permeability coefficients in vivo via modificationof endothelialglycocalyx. Cardiovasc Res 83: 24-33, 2009
49. Chappell D, Jacob M, Hofmann-Kiefer K, Bruegger D, Rehm M, Conzen P, Welsch U, Becker BF: Hydrocortisone preserves the vascular barrier by protecting the endothelial glycocalyx. Anesthesiology 107: 776-784, 2007
50. Weinbaum S, Tarbell JM, Damiano ER: The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng 9: 121-167, 2007
51. Breyer MD, Böttinger E, Brosius FC 3rd, Coffman TM, Harris RC, Heilig CW, Sharma K; AMDCC: Mouse models of diabetic nephropathy. J Am Soc Nephrol 16: 27-45, 2005
52. Palm F, Ortsäter H, Hansell P, Liss P, Carlsson PO: Differentiating between effects of streptozotocin per se and subsequent hyperglycemia on renal function and metabolism in the streptozotocin-diabetic rat model. Diabetes Metab Res Rev 20: 452-459, 2004
53. Qi Z, Whitt I, Mehta A, Jin J, Zhao M, Harris RC, Fogo AB, Breyer MD: Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 286: F590-F596, 2004
54. Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, Xing CY, Ni L, Mathieson PW, Mundel P: A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 13: 630-638, 2002
55. Whittles CE, Pocock TM, Wedge SR, Kendrew J, Hennequin LF, Harper SJ, Bates DO: ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity. Microcirculation 9: 513-522, 2002
56. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A: Fiji: An open-source platform for biological-image analysis. Nat Methods 9: 676-682, 2012